Search

Your search keyword '"Larrat S"' showing total 11 results
Start Over Author "Larrat S" Journal journal of hepatology
11 results on '"Larrat S"'

1. Retreatment with Direct Active Antivirals of genotype 1, 3 and 4 chronic hepatitis C patients who previously failed an anti-NS5A-containing regimen in real world

Author

Halfon, P., primary, Scholtes, C., additional, Izopet, J., additional, Larrat, S., additional, Penaranda, G., additional, Trimoulet, P., additional, Zoulim, F., additional, Alric, L., additional, Metivier, S., additional, Bourliere, M., additional, Leroy, V., additional, Ouzan, D., additional, de Ledinghen, V., additional, Mohamed, S., additional, Thelu, M.-A., additional, and Abravanel, F., additional

Published
2017
Full Text
View/download PDF

9. Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world.

Author

Halfon P, Scholtès C, Izopet J, Larrat S, Trimoulet P, Zoulim F, Alric L, Métivier S, Leroy V, Ouzan D, de Lédinghen V, Mohamed S, Pénaranda G, Khiri H, Thélu MA, Plauzolles A, Chiche L, Bourlière M, and Abravanel F

Subjects
Drug Resistance, Viral, Humans, Treatment Outcome, Antiviral Agents classification, Antiviral Agents pharmacology, Hepacivirus drug effects, Hepacivirus genetics, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic virology, Retreatment methods
Published
2018
Full Text
View/download PDF

11. Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy.

Author

Piroth L, Carrat F, Larrat S, Goderel I, Martha B, Payan C, Lunel-Fabiani F, Bani-Sadr F, Perronne C, Cacoub P, Pol S, and Morand P

Subjects
Adult, Antiretroviral Therapy, Highly Active, Comorbidity, DNA Virus Infections drug therapy, DNA Virus Infections epidemiology, Drug Therapy, Combination, Female, Flaviviridae Infections drug therapy, Flaviviridae Infections epidemiology, GB virus C, HIV Infections drug therapy, HIV Infections epidemiology, Hepatitis B, Chronic drug therapy, Hepatitis B, Chronic epidemiology, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic epidemiology, Hepatitis, Viral, Human drug therapy, Hepatitis, Viral, Human epidemiology, Humans, Interferon alpha-2, Male, Middle Aged, Polyethylene Glycols, Prevalence, Recombinant Proteins, Torque teno virus, Antiviral Agents administration & dosage, Interferon-alpha administration & dosage, Ribavirin administration & dosage, Virus Diseases drug therapy, Virus Diseases epidemiology
Abstract

Background/aims: It has been suggested that, in HIV-HCV co-infected patients, co-infections with other viruses may affect the response to HCV therapy. We aimed to assess the prevalence of GBV-C, SEN-V and occult HBV infections, their impact on HCV and HIV infections and on the response to HCV therapy in HIV-HCV co-infected patients., Methods: Three-hundred and sixty eight patients were tested before starting interferon-ribavirin for the presence of occult hepatitis B DNA, GBV-C RNA and SEN-V DNA by using real time PCR. Clinical, immunological, virological, histological characteristics and response to HCV therapy were compared according to the presence or not of each viral co-infection., Results: HBV DNA, GBV-C RNA and SEN-V DNA were found in 5 (1.4%, CI95%: 0.2-2.4%), 104 (29.9%, CI95%: 25.1-34.7%) and 209 patients (57.9%, CI95%: 52.8-63.0%), respectively. GBV-C positive patients had significantly higher CD4 count at baseline, during and after HCV therapy, even after stratification on antiretroviral treatment. No other significant difference was observed according to the presence or not of GBV-C or SEN-V co-infection, in particular regarding virological responses to HCV combination therapy., Conclusions: There is no reason to withhold HCV therapy in HIV infected patients who have access to HAART, because of occult HBV, GBV-C or SEN-V co-infections.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results